262 related articles for article (PubMed ID: 36999986)
1. The Preclinical Pharmacology of Tepotinib-A Highly Selective MET Inhibitor with Activity in Tumors Harboring MET Alterations.
Albers J; Friese-Hamim M; Clark A; Schadt O; Walter-Bausch G; Stroh C; Johne A; Karachaliou N; Blaukat A
Mol Cancer Ther; 2023 Jul; 22(7):833-843. PubMed ID: 36999986
[TBL] [Abstract][Full Text] [Related]
2. Tepotinib in Non-Small-Cell Lung Cancer with
Paik PK; Felip E; Veillon R; Sakai H; Cortot AB; Garassino MC; Mazieres J; Viteri S; Senellart H; Van Meerbeeck J; Raskin J; Reinmuth N; Conte P; Kowalski D; Cho BC; Patel JD; Horn L; Griesinger F; Han JY; Kim YC; Chang GC; Tsai CL; Yang JC; Chen YM; Smit EF; van der Wekken AJ; Kato T; Juraeva D; Stroh C; Bruns R; Straub J; Johne A; Scheele J; Heymach JV; Le X
N Engl J Med; 2020 Sep; 383(10):931-943. PubMed ID: 32469185
[TBL] [Abstract][Full Text] [Related]
3. Therapeutic strategies in METex14 skipping mutated non-small cell lung cancer.
Drusbosky LM; Dawar R; Rodriguez E; Ikpeazu CV
J Hematol Oncol; 2021 Aug; 14(1):129. PubMed ID: 34425853
[TBL] [Abstract][Full Text] [Related]
4. Tepotinib plus gefitinib in patients with EGFR-mutant non-small-cell lung cancer with MET overexpression or MET amplification and acquired resistance to previous EGFR inhibitor (INSIGHT study): an open-label, phase 1b/2, multicentre, randomised trial.
Wu YL; Cheng Y; Zhou J; Lu S; Zhang Y; Zhao J; Kim DW; Soo RA; Kim SW; Pan H; Chen YM; Chian CF; Liu X; Tan DSW; Bruns R; Straub J; Johne A; Scheele J; Park K; Yang JC;
Lancet Respir Med; 2020 Nov; 8(11):1132-1143. PubMed ID: 32479794
[TBL] [Abstract][Full Text] [Related]
5. Biophysical and structural characterization of the impacts of MET phosphorylation on tepotinib binding.
Grädler U; Schwarz D; Wegener A; Eichhorn T; Bandeiras TM; Freitas MC; Lammens A; Ganichkin O; Augustin M; Minguzzi S; Becker F; Bomke J
J Biol Chem; 2023 Nov; 299(11):105328. PubMed ID: 37806493
[TBL] [Abstract][Full Text] [Related]
6. Dramatic intracranial response to tepotinib in a patient with lung adenocarcinoma harboring MET exon 14 skipping mutation.
Takamori S; Matsubara T; Fujishita T; Ito K; Toyozawa R; Seto T; Yamaguchi M; Okamoto T
Thorac Cancer; 2021 Mar; 12(6):978-980. PubMed ID: 33533182
[TBL] [Abstract][Full Text] [Related]
7. MET-Targeted Therapies and Clinical Outcomes: A Systematic Literature Review.
Dong Y; Xu J; Sun B; Wang J; Wang Z
Mol Diagn Ther; 2022 Mar; 26(2):203-227. PubMed ID: 35266116
[TBL] [Abstract][Full Text] [Related]
8. Emerging MET tyrosine kinase inhibitors for the treatment of non-small cell lung cancer.
Fujino T; Suda K; Mitsudomi T
Expert Opin Emerg Drugs; 2020 Sep; 25(3):229-249. PubMed ID: 32615820
[TBL] [Abstract][Full Text] [Related]
9. Foretinib can overcome common on-target resistance mutations after capmatinib/tepotinib treatment in NSCLCs with MET exon 14 skipping mutation.
Fujino T; Suda K; Koga T; Hamada A; Ohara S; Chiba M; Shimoji M; Takemoto T; Soh J; Mitsudomi T
J Hematol Oncol; 2022 Jun; 15(1):79. PubMed ID: 35690785
[TBL] [Abstract][Full Text] [Related]
10. Tepotinib Efficacy in a Patient with Non-Small Cell Lung Cancer with Brain Metastasis Harboring an HLA-DRB1-MET Gene Fusion.
Blanc-Durand F; Alameddine R; Iafrate AJ; Tran-Thanh D; Lo YC; Blais N; Routy B; Tehfé M; Leduc C; Romeo P; Stephenson P; Florescu M
Oncologist; 2020 Nov; 25(11):916-920. PubMed ID: 32716573
[TBL] [Abstract][Full Text] [Related]
11. Combined therapy with mutant-selective EGFR inhibitor and Met kinase inhibitor for overcoming erlotinib resistance in EGFR-mutant lung cancer.
Nakagawa T; Takeuchi S; Yamada T; Nanjo S; Ishikawa D; Sano T; Kita K; Nakamura T; Matsumoto K; Suda K; Mitsudomi T; Sekido Y; Uenaka T; Yano S
Mol Cancer Ther; 2012 Oct; 11(10):2149-57. PubMed ID: 22844075
[TBL] [Abstract][Full Text] [Related]
12. Tepotinib hydrochloride for the treatment of non-small cell lung cancer.
Wu ZX; Li J; Dong S; Lin L; Zou C; Chen ZS
Drugs Today (Barc); 2021 Apr; 57(4):265-275. PubMed ID: 33851690
[TBL] [Abstract][Full Text] [Related]
13. Targeted Therapy Approaches for MET Abnormalities in Non-Small Cell Lung Cancer.
Garon EB; Brodrick P
Drugs; 2021 Apr; 81(5):547-554. PubMed ID: 33638808
[TBL] [Abstract][Full Text] [Related]
14. Population pharmacokinetic analysis of tepotinib, an oral MET kinase inhibitor, including data from the VISION study.
Xiong W; Papasouliotis O; Jonsson EN; Strotmann R; Girard P
Cancer Chemother Pharmacol; 2022 May; 89(5):655-669. PubMed ID: 35385993
[TBL] [Abstract][Full Text] [Related]
15. Tepotinib in patients with NSCLC harbouring MET exon 14 skipping: Japanese subset analysis from the Phase II VISION study.
Sakai H; Morise M; Kato T; Matsumoto S; Sakamoto T; Kumagai T; Tokito T; Atagi S; Kozuki T; Tanaka H; Chikamori K; Shinagawa N; Takeoka H; Bruns R; Straub J; Schumacher KM; Paik PK
Jpn J Clin Oncol; 2021 Aug; 51(8):1261-1268. PubMed ID: 34037224
[TBL] [Abstract][Full Text] [Related]
16. Prolonged survival and response to tepotinib in a non-small-cell lung cancer patient with brain metastases harboring
Roth KG; Mambetsariev I; Salgia R
Cold Spring Harb Mol Case Stud; 2020 Dec; 6(6):. PubMed ID: 33335011
[TBL] [Abstract][Full Text] [Related]
17. Capmatinib for patients with non-small cell lung cancer with MET exon 14 skipping mutations: A review of preclinical and clinical studies.
Wu YL; Smit EF; Bauer TM
Cancer Treat Rev; 2021 Apr; 95():102173. PubMed ID: 33740553
[TBL] [Abstract][Full Text] [Related]
18. Does c-Met remain a rational target for therapy in patients with EGFR TKI-resistant non-small cell lung cancer?
Wu YL; Soo RA; Locatelli G; Stammberger U; Scagliotti G; Park K
Cancer Treat Rev; 2017 Dec; 61():70-81. PubMed ID: 29121501
[TBL] [Abstract][Full Text] [Related]
19. Current mechanism of acquired resistance to epidermal growth factor receptor-tyrosine kinase inhibitors and updated therapy strategies in human nonsmall cell lung cancer.
Zhang K; Yuan Q
J Cancer Res Ther; 2016 Dec; 12(Supplement):C131-C137. PubMed ID: 28230005
[TBL] [Abstract][Full Text] [Related]
20. Brain penetration and efficacy of tepotinib in orthotopic patient-derived xenograft models of MET-driven non-small cell lung cancer brain metastases.
Friese-Hamim M; Clark A; Perrin D; Crowley L; Reusch C; Bogatyrova O; Zhang H; Crandall T; Lin J; Ma J; Bachner D; Schmidt J; Schaefer M; Stroh C
Lung Cancer; 2022 Jan; 163():77-86. PubMed ID: 34942492
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]